TNF and Crohn disease: Similarly, data from a multicentre study in 552 persons younger than age 17 diagnosed with inflammatory (non-penetrating, nonstricturing) Crohn’s disease between 2008 and 2012 at 28 paediatric gastroenterology centres in North America found that treatment with anti-TNFα therapy within three months of diagnosis was superior to early treatment with an immunomodulator alone (85.3% vs. 60.3% in remission; relative risk: 1.41; 95% CI: 1.14 to 1.75; p = 0.002) in achieving clinical remission at one year (14).